Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury

BJU International

Volumn 98, Issue 1, 2006, Pages 77-82

  Patki, Prasad S ^a,c   Hamid, Rizwan ^a   Arumugam, Kirupakar ^a   Shah, P Julian R ^a,b   Craggs, Mike ^a,b  

^a RNOH Stanmore   (United Kingdom)

^b INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^c ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

English botulinum toxin; Neurogenic bladder; Resistant; Spinal cord injury

Indexed keywords

BOTULINUM TOXIN A; OXYBUTYNIN; TOLTERODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINENCE; CYSTOMETRY; DETRUSOR DYSSYNERGIA; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROGENIC BLADDER; OUTCOME VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SPINAL CORD INJURY;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; BOTULINUM TOXIN TYPE A; DAY CARE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SPINAL CORD INJURIES; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE;

EID: 33745016598     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06192.x     Document Type: Article

References (41)

1. Sekhon LH Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 2001 26 ( Suppl. 24 S2 12
2. Bennett N O'Leary M Patel AS Xavier M Erickson JR Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004 171: 749 51
3. Szollar SM Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 1996 34: 284 7
4. Chapple CR. Fesoterodine a new effective and well tolerated antimuscarinic for the treatment of urgency frequency syndrome: results of a phase 2 controlled study. Neurourol Urodyn 2004 23: 395, Abstract 142
5. Chapple CR. Darifenacin is effective in improving the major symptoms of overactive bladder: a pooled analysis of phase III studies. Eur Urol Suppl 2004 3: 130, Abstract 512
6. Haab F Cardozo L Chapple C Ridder AM Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 47: 376 84
7. Lazzeri M Spinelli M Zanollo A Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 2004 72: 145 9
8. Giannantoni A Di Stasi S Stephen R et al. Intravesical resiniferotoxin versus botulinum-A toxin injections for the treatment of neurogenic detrusor overactivity. Eur Urol Suppl 2004 3: 169, Abstract 665
9. Van Kerrebroeck P Van Voskuilen A Lycklama A et al. Long term results of InterStim therapy for voiding disorders demonstrate sustained efficacy and acceptable safety profile. Eur Urol Suppl 2004 3: 170, Abstract 670
10. Guys JM Haddad M Planche D Torre M Louis-Borrione C Breaud J. Sacral neuromodulation for neurogenic bladder dysfunction in children. J Urol 2004 172: 1673 6
11. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982 46: 86 94
12. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986 26: 427 53
13. Foran PG Mohammed N Lisk GO et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003 278: 1363 71
14. Schurch B Stohrer M Kramer G Schmid DM Gaul G Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000 164: 692 7
15. Dykstra DD Sidi AA Scott AB Pagel JM Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988 139: 919 22
16. Reitz A Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004 171: 804 5
17. Phelan MW Franks M Somogyi GT et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001 165: 1107 10
18. Smith CP O'Leary M Erickson J Somogyi GT Chancellor MB. Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct 2002 13: 185 6
19. Zermann D Ishigooka M Schubert J Schmidt RA. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 2000 38: 393 9
20. Maria G Destito A Lacquaniti S Bentivoglio AR Brisinda G Albanese A. Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 1998 352: 625
21. Kessler TM Danuser H Schumacher M Studer UE Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005 24: 231 6
22. Del Popolo G Li Marzi V Panariello G Lombardi G. English botulinum toxin A in the treatment of neurogenic detrusor overactivity. Neurourol Urodyn 2003 22: 498 499
23. Ranoux D Gury C Fondarai J Mas JL Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002 72: 459 62
24. Whurr R Nye C Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 1998 33 ( Suppl. 327 9
25. Avery K Donovan J Peters TJ Shaw C Gotoh M Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004 23: 322 30
26. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980 17: 21 5
27. Dickson EC Shevky R. Studies on the manner in which the toxin of clostridium botulinum acts upon the body. I. The effect upon the autonomic nervous system. J Exp Med 1923 37: 711 31
28. Reitz A Stohrer M Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004 45: 510 5
29. Grosse J Kramer G Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005 47: 653 9
30. Grosse JO Kramer G Lochner-Ernst D Stohrer M. Outcome of repeat detrusor injections of botulinum toxin (BTX-A) for severe neurogenic detrusor overactivity and incontinence. J Urol 2003 169: 373
31. Schurch B de Seze M Denys P et al. Botulinum toxin A (botox) in neurogenic urinary incontinence: results from a multicentre randomised controlled trial. Neurourol Urodyn 2004 23: 395, Abstract 151
32. Riccabona M Koen M Schindler M et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004 171: 845 8
33. Schurch B de Seze M Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005 174: 196 200
34. Van den Bergh PY Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998 78: 231 5
35. Leippold T Reitz A Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003 44: 165 74
36. Schurch B Corcos J. Botulinum toxin injections for paediatric incontinence. Curr Opin Urol 2005 15: 264 7
37. Haferkamp A Schurch B Reitz A et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004 46: 784 91
38. Harper M Popat RB Dasgupta R Fowler CJ Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003 92: 325 6
39. Cui M Khanijou S Rubino J Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004 107: 125 33
40. Welch MJ Purkiss JR Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000 38: 245 58
41. Vemulakonda VM Somogyi GT Kiss S Salas NA Boone TB Smith CP. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005 173: 621 4